NCT04484402

Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells

Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Limbal Stem Cells (Corneal Epithelial Stem Cells) or Adipose-derived Mesenchymal Stem Cells

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Treatment of patients with inflammatory-dystrophic diseases of the cornea using autologous limbal stem cells (corneal epithelial stem cells) or adipose-derived mesenchymal stem cells

Detailed description

In order to treat inflammatory and dystrophic diseases of the cornea perilimbal injections of cultured autologous stem cells are performed. Corneal (limbal) epithelial stem cells (LSC) or mesenchymal stem cells derived from adipose tissue (ADSC) are mixed with sodium hyaluronate 1%

Conditions

• Corneal Ulcer
• Corneal Disease
• Corneal Dystrophy

Interventions

Type	Name	Description
BIOLOGICAL	mesenchymal stem cells	Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
BIOLOGICAL	limbal stem cells	Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
OTHER	standard treatment	Standard treatment according to the Clinical protocols

Timeline

• Start date: 2016-10-03
• Primary completion: 2019-12-30
• Completion: 2019-12-30
• First posted: 2020-07-23
• Last updated: 2020-07-30

Locations

1 site across 1 country: Belarus